Stocklytics Platform
Asset logo for symbol SRPT
Sarepta Therapeutics
SRPT58
$117.79arrow_drop_down2.16%-$2.60
Asset logo for symbol SRPT
SRPT58

$117.79

arrow_drop_down2.16%

AI Deep-Learning Forecast (SRPT)

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Sarepta Therapeutics (SRPT) Stocklytics Forecast

Sarepta Therapeutics Inc (SRPT) is a biopharmaceutical company that focuses on the development and commercialization of innovative RNA-targeted therapeutics. With a strong pipeline of potential treatments for rare genetic diseases, Sarepta has captured the attention of investors and analysts alike. In terms of stock price prediction, many experts believe that SRPT has significant growth potential in the coming years.
According to AI and machine learning predictions, Sarepta Therapeutics Inc (SRPT) is expected to experience positive momentum in its stock price. These algorithms analyze historical data, market trends, and various other factors to provide reliable forecasts. While the accuracy of these predictions cannot be guaranteed, they can be a valuable tool for investors looking to make informed decisions.
add Sarepta Therapeutics  to watchlist

Keep an eye on Sarepta Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for Sarepta Therapeutics (SRPT) stock?

Analysts have set a target price of $146.5 for Sarepta Therapeutics (SRPT), based on forecasts from 30 analysts. The predicted price range extends from a high of $224 to a low of $40. This represents a potential increase of up to 90.17% and a decrease of -66.04% from the current price of $117.79. These forecasts are as of 2023 Oct 31.
help

What are the analyst ratings for Sarepta Therapeutics (SRPT) stock?

The analyst ratings for Sarepta Therapeutics (SRPT) are distributed as follows: 17 analysts recommend buying, 1 have a neutral stance, and 0 suggest selling. The prevailing sentiment among the total of 18 analysts leans towards a buy rating. These ratings indicate the general sentiment among the analysts covering Sarepta Therapeutics .
help

What is the AI price prediction for Sarepta Therapeutics (SRPT) stock?

At present, there is no AI or machine-learning-based price prediction available for Sarepta Therapeutics (SRPT) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media